Aeterna Zentaris (AEZS) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results
March 15, 2017 4:48 PM EDTClinical phase of Zoptrex and Macrilen development programs completed; Zoptrex top-line results expected in April
All amounts are in US Dollars
Recent key developments
Development programs progressing toward completion Zoptrex (zoptarelin doxorubicin) pivotal Phase 3 trial clinically completed on January 30, 2017; pre-NDA meeting with FDA held on January 31, 2017; top-line results expected to be reported in April 2017 Company believes that analysis of data from confirmatory Phase 3 trial of Macrilen (macimorelin) is supportive of registration consideration; Meeting with FDA will be held at the end of Q1... More